These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 1498260)
1. Anti-tumor cytotoxic potential and effect on human bone marrow GM-CFU of human LAK cells generated in response to various cytokines. Parhar RS; Ernst P; Sheth KV; al-Sedairy ST Eur Cytokine Netw; 1992; 3(3):299-306. PubMed ID: 1498260 [TBL] [Abstract][Full Text] [Related]
2. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4. Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200 [TBL] [Abstract][Full Text] [Related]
3. The lack of NK cytotoxicity associated with fresh HUCB may be due to the presence of soluble HLA in the serum. Webb BJ; Bochan MR; Montel A; Padilla LM; Brahmi Z Cell Immunol; 1994 Dec; 159(2):246-61. PubMed ID: 7994757 [TBL] [Abstract][Full Text] [Related]
4. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma. Broxmeyer HE; Williams DE; Lu L; Cooper S; Anderson SL; Beyer GS; Hoffman R; Rubin BY J Immunol; 1986 Jun; 136(12):4487-95. PubMed ID: 3086433 [TBL] [Abstract][Full Text] [Related]
5. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor. Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733 [TBL] [Abstract][Full Text] [Related]
6. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing. Wiebke EA; Custer MC; Rosenberg SA; Lotze MT J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373 [TBL] [Abstract][Full Text] [Related]
7. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells. Saarloos MN; Khoo NK; Lala PK Cancer Res; 1992 Dec; 52(23):6452-62. PubMed ID: 1423293 [TBL] [Abstract][Full Text] [Related]
8. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues. Colquhoun SD; Economou JS; Shau H; Golub SH J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167 [TBL] [Abstract][Full Text] [Related]
9. Mechanism of suppression of normal hemopoietic activity by lymphokine-activated killer cells and their products. Gibson FM; Malkovska V; Myint AA; Meager A; Gordon-Smith EC Exp Hematol; 1991 Aug; 19(7):659-63. PubMed ID: 1909968 [TBL] [Abstract][Full Text] [Related]
10. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation. Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943 [TBL] [Abstract][Full Text] [Related]
11. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma. Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355 [TBL] [Abstract][Full Text] [Related]
12. Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells. Aste-Amezaga M; D'Andrea A; Kubin M; Trinchieri G Cell Immunol; 1994 Jul; 156(2):480-92. PubMed ID: 7912999 [TBL] [Abstract][Full Text] [Related]
13. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285 [TBL] [Abstract][Full Text] [Related]
14. Interleukin-12 (IL-12) alone or in synergistic combination with IL-2 for in vitro activation of human bone marrow: differential effects at different time points. Verma UN; Mazumder A Bone Marrow Transplant; 1995 Sep; 16(3):365-72. PubMed ID: 8535308 [TBL] [Abstract][Full Text] [Related]
15. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor. Chong AS; Scuderi P; Grimes WJ; Hersh EM J Immunol; 1989 Mar; 142(6):2133-9. PubMed ID: 2493506 [TBL] [Abstract][Full Text] [Related]
16. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma. Muralikrishna K; Varalakshmi C; Khar A Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244 [TBL] [Abstract][Full Text] [Related]
17. Suppression of human monocyte function against Candida albicans by autologous IL-2-induced lymphokine-activated killer cells. Wei S; Serbousek D; McMillen S; Blanchard DK; Djeu JY J Immunol; 1991 Jan; 146(1):337-42. PubMed ID: 1898605 [TBL] [Abstract][Full Text] [Related]
18. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties. Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186 [TBL] [Abstract][Full Text] [Related]
19. Dual effects of cytokines in regulation of MHC-unrestricted cell mediated cytotoxicity. Reiter Z Crit Rev Immunol; 1993; 13(1):1-34. PubMed ID: 8466640 [TBL] [Abstract][Full Text] [Related]
20. Mannoprotein-induced anti-U937 cell cytotoxicity in peripheral blood mononuclear cells from uninfected or HIV-infected subjects: role of interferon-gamma and tumor necrosis factor-alpha. Gomez MJ; Torosantucci A; Quinti I; Testa U; Peschle C; Cassone A Cell Immunol; 1993 Dec; 152(2):530-43. PubMed ID: 8258154 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]